This is a Phase 3 clinical study for adults 18 years and older with Chronic Rhinosinusitis (long-term sinus inflammation) and Nasal Polyps that hasn’t responded well to prior treatment with systemic corticosteroids (SCS) or when those treatments aren’t suitable.
The study will test a new injectable medication called amlitelimab to see how safe and effective it is compared to a placebo.
What to Expect
- Participants will be randomly assigned to one of three groups.
- Two groups will receive the Librikizumab subcutaneous injection, and one group will receive a placebo (a treatment without active medication).
- Neither participants nor the researchers will know who is in which group during the study.
Treatment Period
- 18 Months
Trial Requirements
- Age 18+
Urgently Recruiting
Trial Details
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
